Sana Biotechnology, Inc. 2020 Form 10-K Summary
Business context and reporting period
Sana Biotechnology is a preclinical-stage biotechnology company developing engineered-cell medicines through in vivo and ex vivo cell-engineering platforms. The filing covers the fiscal year ended December 31, 2020. All product candidates remained in preclinical development; the company had no approved products, no clinical trials, and no product-sale revenue.
- In vivo platform: Fusosome technology intended to deliver genetic payloads to specific cells, initially targeting T cells, hepatocytes, and hematopoietic stem cells.
- Ex vivo platform: Hypoimmune allogeneic cells designed to evade adaptive and innate immune rejection, including programs involving T cells, beta cells, glial progenitor cells, and cardiomyocytes.
- Pipeline: Management targeted multiple IND filings beginning as early as 2022, including candidates for CAR T therapy, OTC deficiency, and allogeneic CAR T therapy, with additional programs targeted for 2023.
Financial results, liquidity, and capital resources
| Metric | 2020 | 2019 | Change |
|---|---|---|---|
| Revenue | None from product sales or other sources | None from product sales or other sources | None |
| Research and development expense | $257.9 million | $119.4 million | +$138.5 million |
| General and administrative expense | $28.3 million | $21.8 million | +$6.5 million |
| Total operating expenses | $286.1 million | $141.2 million | +$145.0 million |
| Operating loss | $286.1 million | $141.2 million | +$145.0 million |
| Net loss | $285.3 million | $130.8 million | +$154.5 million |
| Net loss per share | $21.92 | $26.68 | Loss per share decreased |
| Cash used in operating activities | $138.0 million | $85.5 million | +$52.5 million use |
| Cash, cash equivalents, and marketable securities | $412.0 million | $139.0 million | +$273.0 million |
| Debt outstanding | None | None reported | No debt |
Profit margins are not meaningful because the company had no revenue and incurred operating losses. Net loss increased primarily because of expanded research and development activity and significant non-cash remeasurement charges.
- Operating cash flow was negative $138.0 million. Non-cash adjustments included $72.1 million for success-payment liabilities and $52.8 million for contingent consideration.
- Investing cash flow was negative $252.6 million, including $228.7 million of net purchases, sales, and maturities of marketable securities and $23.9 million of property and equipment purchases.
- Financing cash flow was $435.7 million, primarily from the June 2020 issuance of Series B convertible preferred stock.
- Working capital was $353.0 million; total assets were $730.3 million; accumulated deficit was $429.4 million.
- Contingent consideration was recorded at $121.9 million and success-payment liabilities at $76.5 million at year-end.
Material changes versus the prior comparable period
- Research and development expense more than doubled, reflecting higher personnel, laboratory, preclinical, facility, and platform-development spending.
- Non-cash remeasurement expense increased materially: success-payment expense rose to $72.1 million from $1.9 million, and contingent-consideration expense rose to $52.8 million from $17.9 million.
- Headcount expanded substantially as the company built research, manufacturing, regulatory, and administrative capabilities. The filing reports 265 employees at December 31, 2020, including 206 primarily engaged in research and development.
- The company acquired Oscine in September 2020 for $8.5 million, recording the purchase price as research and development expense because the acquired in-process research and development had no alternative future use.
- Cash and marketable securities increased primarily because of the $435.6 million gross Series B preferred-stock financing, partly offset by operating losses, capital expenditures, and investment purchases.
Guidance, outlook, commentary, risks, and unusual items
- Management expected expenses and operating losses to increase substantially as it advances preclinical programs, begins clinical studies, expands manufacturing capabilities, seeks regulatory approvals, and operates as a public company.
- In February 2021, after the reporting period, Sana completed its IPO, issuing approximately 27.0 million shares at $25.00 per share and receiving $626.6 million of net proceeds. All outstanding convertible preferred stock converted into common stock.
- Management stated that year-end liquidity plus IPO proceeds should fund operating and capital requirements for at least 36 months based on current plans, but acknowledged that additional financing will likely be required in the future.
- Potential obligations include up to $500.0 million of Cobalt contingent consideration, up to $500.0 million of a Cobalt success payment payable in cash or stock, and up to $175.0 million of Harvard success payments. These obligations may create dilution, cash demands, debt, and significant earnings volatility.
- Operating lease commitments totaled $119.5 million, including $14.1 million due within one year.
- COVID-19 caused modest delays in discovery and development activities, temporary or partial shutdowns at certain CROs and academic institutions, supply delays, and restrictions on laboratory and animal-model access. Future effects remained uncertain.
- Key risks include failure of novel technologies, inability to translate preclinical results into human safety or efficacy, regulatory delays or clinical holds, manufacturing scale-up and quality risks, dependence on third parties, intellectual-property challenges, additional capital needs, dilution, and retention of specialized personnel.
- Unusual accounting items materially affected reported results. The year-end fair values of the Cobalt success-payment liability and contingent consideration rose from $2.4 million and $69.1 million in 2019 to $64.7 million and $121.9 million, respectively, while the Harvard success-payment liability rose from $1.9 million to $11.8 million.
Most important facts for an investor to verify
- Whether the company’s preclinical data translate into safe and effective human therapies and whether targeted IND filings occur on the stated timelines.
- The cash-burn rate, updated liquidity runway after the IPO, capital expenditures, and timing and terms of future financing.
- The probability, timing, valuation triggers, and settlement method for Cobalt and Harvard success payments and other milestone obligations.
- Progress toward scalable GMP manufacturing, reliance on CDMOs, supply-chain resilience, and regulatory acceptance of manufacturing processes.
- Clinical, regulatory, and safety risks associated with gene editing, genome integration, hypoimmune cells, tumorigenicity, immunogenicity, cytokine release syndrome, graft-versus-host disease, neurotoxicity, and arrhythmias.
- Patent ownership, license diligence requirements, royalty and milestone obligations, and the durability and enforceability of the company’s intellectual-property portfolio.
- Effects of COVID-19 or other disruptions on animal studies, CROs, clinical development, manufacturing, regulatory review, and access to capital.